SCHEMBL17603345

SCHEMBL17603345

Cc1cc(Cl)cc2cc(C=O)c(=O)[nH]c12

nearest known ligand 0.42

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
GRIA1 P42261 1/20 0.42
GRIA2 P42262 1/20 0.42
GRIA3 P42263 1/20 0.42
GRIA4 P48058 1/20 0.42
HRH4 Q9H3N8 5/20 0.42
CYP1A2 P05177 1/20 0.39
CYP3A4 P08684 1/20 0.39
CYP2D6 P10635 1/20 0.39
CYP2C19 P33261 1/20 0.39
IDH1 O75874 1/20 0.39
GRIN2D O15399 4/20 0.37
GRIN3B O60391 4/20 0.37
GRIN1 Q05586 4/20 0.37
GRIN2A Q12879 4/20 0.37
GRIN2B Q13224 4/20 0.37
GRIN2C Q14957 4/20 0.37
GRIN3A Q8TCU5 4/20 0.37
HSD17B10 Q99714 2/20 0.37
ERN1 O75460 2/20 0.36
ALDH1A1 P00352 4/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4070484 0.83 HSD17B10 (0.52) GRIA1GRIA2GRIA3GRIA4HRH4
SCHEMBL17603328 0.80 ERN1 (0.44) GRIA1GRIA2GRIA3GRIA4IDH1
SCHEMBL17603348 0.80 ERN1 (0.50) IDH1GRIN2DGRIN3BGRIN1GRIN2A
SCHEMBL3421507 0.78 DAO (0.58) HRH4IDH1GRIN2DGRIN3BGRIN1
SCHEMBL4071083 0.77 DAO (0.61) GRIA1GRIA2GRIA3GRIA4HSD17B10
SCHEMBL2310258 0.74 KDM4E (0.51) HRH4CYP1A2IDH1HSD17B10ALDH1A1
SCHEMBL5449128 0.73 HSD17B10 (0.47) GRIA1GRIA2GRIA3GRIA4HSD17B10
SCHEMBL29951711 0.73 HSD17B10 (0.47) GRIA1GRIA2GRIA3GRIA4HSD17B10
SCHEMBL21734885 0.73 HRH4 (0.39) HRH4IDH1GRIN2DGRIN3BGRIN1
SCHEMBL14115020 0.72 HRH4 (0.45) HRH4CYP1A2IDH1ALDH1A1KDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20190210970-A1 PHENYL QUINOLINONE DERIVATIVES AS MUTANT-ISOCITRATE DEHYDROGENASE INHIBITORS FORMA THERAPEUTICS, INC. 2019-07-11 US disclosed
US-20190210970-A1 PHENYL QUINOLINONE DERIVATIVES AS MUTANT-ISOCITRATE DEHYDROGENASE INHIBITORS FORMA THERAPEUTICS, INC. 2019-07-11 US disclosed
US-10266495-B2 Phenyl quinolinone derivatives as mutant-isocitrate dehydrogenase inhibitors FORMA TM2, INC. (US) 2019-04-23 US disclosed
US-10266495-B2 Phenyl quinolinone derivatives as mutant-isocitrate dehydrogenase inhibitors FORMA TM2, INC. (US) 2019-04-23 US disclosed
EP-3194375-B1 PHENYL QUINOLINONE DERIVATIVES AS MUTANT-ISOCITRATE DEHYDROGENASE INHIBITORS FORMA THERAPEUTICS INC (US) 2018-11-21 EP disclosed
US-20180327361-A1 PHENYL QUINOLINONE DERIVATIVES AS MUTANT-ISOCITRATE DEHYDROGENASE INHIBITORS FORMA THERAPEUTICS, INC. 2018-11-15 US disclosed
US-10005734-B2 Pyridin-2(1H)-one quinolinone derivatives as mutant-isocitrate dehydrogenase inhibitors FORMA THERAPEUTICS, INC. (US) 2018-06-26 US disclosed
US-10005734-B2 Pyridin-2(1H)-one quinolinone derivatives as mutant-isocitrate dehydrogenase inhibitors FORMA THERAPEUTICS, INC. (US) 2018-06-26 US disclosed
US-10005734-B2 Pyridin-2(1H)-one quinolinone derivatives as mutant-isocitrate dehydrogenase inhibitors FORMA THERAPEUTICS, INC. (US) 2018-06-26 US disclosed
EP-3194375-A1 PHENYL QUINOLINONE DERIVATIVES AS MUTANT-ISOCITRATE DEHYDROGENASE INHIBITORS Forma Therapeutics, Inc. (US) 2017-07-26 EP disclosed
WO-2016044782-A1 PHENYL QUINOLINONE DERIVATIVES AS MUTANT-ISOCITRATE DEHYDROGENASE INHIBITORS FORMA THERAPEUTICS, INC. (US) 2016-03-24 WO disclosed
US-20160083349-A1 PYRIDIN-2(1H)-ONE QUINOLINONE DERIVATIVES AS MUTANT-ISOCITRATE DEHYDROGENASE INHIBITORS FORMA THERAPEUTICS, INC. 2016-03-24 US disclosed
US-20160083349-A1 PYRIDIN-2(1H)-ONE QUINOLINONE DERIVATIVES AS MUTANT-ISOCITRATE DEHYDROGENASE INHIBITORS FORMA THERAPEUTICS, INC. 2016-03-24 US disclosed
WO-2016044782-A1 PHENYL QUINOLINONE DERIVATIVES AS MUTANT-ISOCITRATE DEHYDROGENASE INHIBITORS FORMA THERAPEUTICS, INC. (US) 2016-03-24 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-10005734-B2 Pyridin-2(1H)-one quinolinone derivatives as mutant-isocitrate dehydrogenase inhibitors IDH3A, IDH1, IDH2 GRIA1 1668/4885GRIA2 2107/4885GRIA3 2287/4885
US-10266495-B2 Phenyl quinolinone derivatives as mutant-isocitrate dehydrogenase inhibitors IDH3A, IDH1, IDH3B GRIA1 2366/4885GRIA2 3169/4885GRIA3 2755/4885
US-20190210970-A1 PHENYL QUINOLINONE DERIVATIVES AS MUTANT-ISOCITRATE DEHYDROGENASE INHIBITORS IDH1, IDH2, IDH3A GRIA1 1843/4885GRIA2 1561/4885GRIA3 2238/4885
US-20160083349-A1 PYRIDIN-2(1H)-ONE QUINOLINONE DERIVATIVES AS MUTANT-ISOCITRATE DEHYDROGENASE INHIBITORS IDH3A, IDH1, IDH2 GRIA1 1668/4885GRIA2 2107/4885GRIA3 2287/4885
US-20180327361-A1 PHENYL QUINOLINONE DERIVATIVES AS MUTANT-ISOCITRATE DEHYDROGENASE INHIBITORS IDH3A, IDH1, IDH3B GRIA1 2366/4885GRIA2 3169/4885GRIA3 2755/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.